Drug Search Results

Fimasartan

Alternative Names: fimasartan, br-a-657, fimsartan
Latest Update: 2024-10-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ARB Blocker,AT1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Boryung
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fimasartan

Countries in Clinic: Korea

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Hypertension

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
BR-FMS-CT-119	P1	Completed	Hypertension	2022-06-04	21%
BR-FMS-CT-119	P1	Completed	Hypertension	2022-06-04	21%

Recent News Events

Date	Type	Title
02/22/2024	PubMed	Podocyte disease following treatment with intravenous ibandronate in an older patient.
01/01/2024	PubMed	Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model.
06/26/2023	PubMed	Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction.
06/15/2022	News Article	Antihypertensive Drugs Market is Estimated to Rise at a CAGR of 3% during the Forecast Period, observes TMR Study
03/26/2020	News Article	COVID-19 Drug Repurposing Datasets Now Available in Collaboration with Vectorspace AI, Amazon & Microsoft

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions